Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.

Biomarkers, Tumor Breast Neoplasms / genetics Chemotherapy, Adjuvant DNA Mutational Analysis Female Genetic Heterogeneity High-Throughput Nucleotide Sequencing Humans Mutation Mutation Rate Neoadjuvant Therapy Odds Ratio Treatment Outcome

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 08 10 2018
revised: 18 02 2019
accepted: 02 04 2019
pubmed: 14 4 2019
medline: 6 8 2020
entrez: 14 4 2019
Statut: ppublish

Résumé

Next-generation sequencing (NGS) can be used for comprehensive investigation of molecular events in breast cancer. We evaluated the relevance of genomic alterations for response to neoadjuvant chemotherapy (NACT) in the GeparSepto trial. Eight hundred fifty-one pretherapeutic formalin-fixed paraffin-embedded (FFPE) core biopsies from GeparSepto study were sequenced. The panel included 16 genes for mutational ( The most common genomic alterations were mutations of High genetic heterogeneity was observed in different breast cancer subtypes. Our study shows that FFPE-based NGS can be used to identify markers of therapy resistance in clinical study cohorts.

Identifiants

DOI: 10.1158/1078-0432.CCR-18-3258 PMID: 30979740
pubmed: 30979740
pii: 1078-0432.CCR-18-3258
doi: 10.1158/1078-0432.CCR-18-3258
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3986-3995

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Sibylle Loibl (S)

German Breast Group, Neu-Isenburg, Germany. Sibylle.Loibl@gbg.de.

Denise Treue (D)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.

Jan Budczies (J)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.
Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Karsten Weber (K)

German Breast Group, Neu-Isenburg, Germany.

Albrecht Stenzinger (A)

German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.
Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

Wolfgang D Schmitt (WD)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.
ORCID: 0000-0002-7870-138X

Wilko Weichert (W)

German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.
Institute of Pathology, Technical University of Munich, Munich, Germany.

Paul Jank (P)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.

Jenny Furlanetto (J)

German Breast Group, Neu-Isenburg, Germany.

Frederick Klauschen (F)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.

Thomas Karn (T)

Department of Gynecology and Obstetrics, University of Frankfurt, Frankfurt am Main, Germany.
ORCID: 0000-0002-3264-6573

Nicole Pfarr (N)

Institute of Pathology, Technical University of Munich, Munich, Germany.
ORCID: 0000-0002-5977-5375

Gunter von Minckwitz (G)

German Breast Group, Neu-Isenburg, Germany.

Markus Möbs (M)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.

Christian Jackisch (C)

Department of Obstetrics and Gynecology and Breast Cancer Center, Sana Klinikum Offenbach, Offenbach, Germany.

Christine Sers (C)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.
ORCID: 0000-0002-6219-1514

Andreas Schneeweiss (A)

National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.

Peter A Fasching (PA)

Universitätsklinikum Erlangen, Erlangen, Germany.
ORCID: 0000-0003-4885-8471

Christian Schem (C)

Mammazentrum Hamburg - Brustklinik am Krankenhaus Jerusalem, Hamburg, Germany.

Michael Hummel (M)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.

Marion van Mackelenbergh (M)

Universitätsklinikum Kiel, Kiel, Germany.

Valentina Nekljudova (V)

German Breast Group, Neu-Isenburg, Germany.

Michael Untch (M)

Helios Klinikum Berlin-Buch, Berlin, Germany.

Carsten Denkert (C)

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Berlin, Germany.
German Cancer Consortium (DKTK), Partner Sites Berlin and Munich, Germany.
Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitement médicamenteux adjuvant › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ADN › Analyse de mutations d'ADN › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Hétérogénéité génétique › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Phénomènes biologiques › Évolution biologique › Évolution moléculaire › Taux de mutation › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Odds ratio › Mutational Diversity and Therapy Response in...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Mutational Diversity and Therapy Response in...